Tag: INO-VATE

US regulators wave through Pfizer’s leukaemia drug

by Selina McKee | Aug 18, 2017 | News | 0

The US Food and Drug Administration has approved Pfizer’s Besponsa, the first and only CD22-directed antibody-drug conjugate indicated to treat relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).

EU nod for Pfizer’s Besponsa

by Selina McKee | Jul 3, 2017 | News | 0

Pfizer’s antibody drug conjugate Besponsa has become the first to be approved by regulators in Europe to treat some adults with the rare, aggressive cancer acute lymphoblastic leukaemia (ALL).